Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Symptoms and clinical manifestations in neuromyelitis optica].
Migration of the Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (Fsiq-Rms(tm)) from Paper to an Electronic Diary Format.
Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies.
Osmotic Demyelination Syndrome as the Initial Manifestation of a Hyperosmolar Hyperglycemic State.
Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.
Sedentary behavior is associated with disability status and walking performance, but not cognitive function, in multiple sclerosis.
Robotic-Assisted Gait Training in Neurological Patients: Who May Benefit?
Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?
[Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
[Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
[Neuroimmunology: theoretical and clinical aspects].
Reimbursement and market access of multiple sclerosis products in the United States.
A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation.
[Progressive Multifocal Leukoencephalopathy with Inflammatory Reactions].
Ozanimod: a better or just another S1P receptor modulator?
The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study.
Patient education programme on immunotherapy in multiple sclerosis (PEPIMS): A controlled rater-blinded study.
[Quality of life in multiple sclerosis--association with clinical features, fatigue and depressive syndrome].
Roles for HB-EGF and CD9 in multiple sclerosis.
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta.
[Natalizumab as induction therapy in multiple sclerosis.]
Isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis.
Employment and multiple sclerosis: Policy, programming, and research recommendations.
Differential Diagnosis for Multiple Sclerosis-related Optic Neuritis.
Disparate Effects of Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis and Cuprizone-Induced Demyelination.
Pages
« first
‹ previous
…
484
485
486
487
488
489
490
491
492
…
next ›
last »